- Home
- EFOI vs NLSP Comparison
EFOI vs NLSP Comparison
Compare EFOI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFOI
- NLSP
- Stock Information
- Founded
- EFOI 1985
- NLSP 2015
- Country
- EFOI United States
- NLSP Switzerland
- Employees
- EFOI N/A
- NLSP N/A
- Industry
- EFOI Building Products
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- EFOI Consumer Discretionary
- NLSP Health Care
- Exchange
- EFOI Nasdaq
- NLSP Nasdaq
- Market Cap
- EFOI 12.1M
- NLSP 12.4M
- IPO Year
- EFOI 1994
- NLSP 2021
- Fundamental
- Price
- EFOI $2.30
- NLSP $2.50
- Analyst Decision
- EFOI
- NLSP
- Analyst Count
- EFOI 0
- NLSP 0
- Target Price
- EFOI N/A
- NLSP N/A
- AVG Volume (30 Days)
- EFOI 22.4K
- NLSP 411.8K
- Earning Date
- EFOI 08-12-2025
- NLSP 07-15-2025
- Dividend Yield
- EFOI N/A
- NLSP N/A
- EPS Growth
- EFOI N/A
- NLSP N/A
- EPS
- EFOI N/A
- NLSP N/A
- Revenue
- EFOI $4,643,000.00
- NLSP N/A
- Revenue This Year
- EFOI N/A
- NLSP N/A
- Revenue Next Year
- EFOI N/A
- NLSP N/A
- P/E Ratio
- EFOI N/A
- NLSP N/A
- Revenue Growth
- EFOI N/A
- NLSP N/A
- 52 Week Low
- EFOI $1.14
- NLSP $1.30
- 52 Week High
- EFOI $2.95
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- EFOI 59.77
- NLSP 52.64
- Support Level
- EFOI $2.21
- NLSP $2.16
- Resistance Level
- EFOI $2.37
- NLSP $3.08
- Average True Range (ATR)
- EFOI 0.21
- NLSP 0.24
- MACD
- EFOI 0.04
- NLSP -0.00
- Stochastic Oscillator
- EFOI 78.57
- NLSP 30.21
About EFOI Energy Focus Inc.
Energy Focus Inc engages in the design, development, manufacturing, marketing, and sale of energy-efficient lighting systems and controls. The company serves the military maritime market and general commercial markets. Its product offerings include Military maritime LED lighting products such as military intelligible, globe lights, berth lights, and military fixtures and Commercial products such as LED fixtures and panels, LED down-lights, LED dock lights, and LED retrofit kits. Geographically, it operates in the United States and other countries. Its products include commercial products and MMM products. The company generates a majority of its sales from Military maritime products in the United States.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.